Epigenetic Regulation Dysfunction in Alzheimer's and Parkinson's Disease

🧫 Experiment Protocol ClinicalAlzheimer's DiseaseBRD4/HDAC/HDAC3humanproposed

# Epigenetic Regulation Dysfunction in Alzheimer's and Parkinson's Disease ## Background and Rationale Neurodegenerative diseases like Alzheimer's (AD) and Parkinson's disease (PD) exhibit complex pathophysiology involving genetic, environmental, and epigenetic factors. Growing evidence suggests that epigenetic dysregulation plays a crucial role in disease onset and progression, affecting gene expression patterns critical for neuronal survival and function. This comprehensive clinical study aims to characterize epigenetic alterations in AD and PD patients compared to healthy controls through multi-omics analysis of post-mortem brain tissue and patient-derived induced pluripotent stem cells (iPSCs). The study employs a case-control design with three cohorts: AD patients (n=60), PD patients (n=60), and age-matched healthy controls (n=40). Primary measurements include genome-wide DNA methylation profiling using reduced representation bisulfite sequencing (RRBS), chromatin immunoprecipitation sequencing (ChIP-seq) for histone modifications (H3K4me3, H3K27me3, H3K9ac), and comprehensive RNA sequencing to assess coding and non-coding RNA expression. Patient-derived iPSCs will be differentiated into dopaminergic and cholinergic neurons to validate findings in disease-relevant cellular models. Advanced bioinformatics approaches will integrate multi-omics data to identify epigenetic signatures associated with neurodegeneration. The innovation lies in the comprehensive multi-layered epigenetic analysis across two major neurodegenerative diseases, enabling identification of common and disease-specific epigenetic mechanisms. This research has significant translational potential for developing epigenetic biomarkers for early diagnosis and monitoring disease progression, while identifying novel therapeutic targets for epigenetic interventions such as DNA methyltransferase inhibitors or histone deacetylase modulators. This experiment directly tests predictions arising from the following hypotheses: - **Selective HDAC3 Inhibition with Cognitive Enhancement** - **Chromatin Accessibility Restoration via BRD4 Modulation** - **Astrocyte-Mediated Neuronal Epigenetic Rescue** - **Temporal TET2-Mediated Hydroxymethylation Cycling** - **TET2-Mediated Demethylation Rejuvenation Therapy** ## Experimental Protocol Phase 1: Sample Collection and Processing (Months 1-6): Collect post-mortem brain tissue from frontal cortex, hippocampus, and substantia nigra regions from AD (n=60), PD (n=60), and control (n=40) subjects. Establish iPSC lines from patient fibroblasts using Sendai virus reprogramming. Phase 2: iPSC Differentiation (Months 4-12): Differentiate iPSCs into dopaminergic neurons using dual-SMAD inhibition protocol with SB431542 and LDN193189, followed by FGF8 and SHH treatment. Generate cholinergic neurons using NGF and BDNF supplementation. Validate neuronal identity using immunofluorescence for TH, ChAT, and MAP2. Phase 3: Epigenetic Profiling (Months 7-18): Extract high-quality DNA and RNA using AllPrep DNA/RNA Mini Kit. Perform RRBS library preparation using MspI digestion and bisulfite conversion. Conduct ChIP-seq using antibodies against H3K4me3, H3K27me3, and H3K9ac with 10μg chromatin per immunoprecipitation. Generate RNA-seq libraries including small RNA fractions using TruSeq protocols. Sequence all libraries on Illumina NovaSeq platform (30M reads minimum per sample). Phase 4: Data Analysis (Months 12-24): Process sequencing data using standard pipelines (Bismark for RRBS, MACS2 for ChIP-seq, STAR for RNA-seq). Identify differentially methylated regions (DMRs), differential histone peaks, and differentially expressed genes using DESeq2 and edgeR with FDR<0.05. Perform pathway enrichment analysis and integrate multi-omics data using machine learning approaches. ## Expected Outcomes - 1. Identification of 500-1000 differentially methylated regions (DMRs) in AD and 400-800 DMRs in PD compared to controls, with effect sizes >20% methylation difference and FDR<0.01. - 2. Discovery of 200-400 genes showing coordinated epigenetic dysregulation (methylation + histone modifications + expression changes) in each disease, with 50-100 overlapping genes between AD and PD. - 3. Detection of 50-100 differentially expressed microRNAs and long non-coding RNAs per disease group, with fold-changes >2.0 and significant correlation (r>0.6) with target gene expression. - 4. Validation of 80% of brain tissue epigenetic findings in corresponding iPSC-derived neuronal models, demonstrating disease-relevant cellular phenotypes. - 5. Development of epigenetic signature panels achieving >85% accuracy for disease classification using machine learning algorithms with cross-validation. - 6. Identification of 20-30 druggable epigenetic targets showing consistent dysregulation across multiple patients and validation systems, prioritized for therapeutic development. ## Success Criteria - • Achieve >90% sample quality metrics for all omics datasets with library complexity >10M unique reads and bisulfite conversion efficiency >98% - • Identify statistically significant epigenetic alterations (FDR<0.05) in >500 genomic loci per disease with consistent direction of change across patients - • Demonstrate successful integration of multi-omics data with correlation coefficients >0.4 between methylation and gene expression changes - • Validate >75% of identified epigenetic biomarkers in independent iPSC-derived neuronal models with reproducible phenotypic changes - • Develop predictive models achieving area under curve (AUC) >0.85 for disease classification using epigenetic signatures - • Identify >15 high-priority therapeutic targets with literature support and druggability scores >0.7 for future intervention studies

Source: wiki

🧫 Experiment Extras

🔴 Alzheimer's Disease 🟢 Parkinson's Disease 🧠 Neurodegeneration

📊 Evidence Profile

0 supporting 0 contradicting 0 neutral

🌍 Provenance Graph 1 nodes, 0 edges

No provenance edges found